Dupixent Q4 2020 Sales Figure
Dupixent (dupilumab) generated $1.37 billion in global sales during Q4 2020, up from $1.14 billion in Q3 2020.[1][2]
Quarter-Over-Quarter Growth
This marked a 20% increase from Q3, driven by expanded U.S. approvals for asthma and chronic rhinosinusitis with nasal polyps, plus strong demand in atopic dermatitis. Sanofi and Regeneron, the co-marketers, attributed the jump to higher patient starts and refill rates amid the COVID-19 pandemic.[1][3]
Full-Year 2020 Context
Annual sales hit $4.0 billion, a 78% rise from 2019, with Q4 acceleration signaling momentum into 2021. U.S. sales alone reached $921 million in Q4, comprising 67% of the total.[1][2]
How It Stacked Up Against Expectations
Q4 beat analyst consensus of $1.32 billion by 4%, boosting shares for both companies post-earnings.[3][4]
[1]: Sanofi Q4 2020 Earnings Release
[2]: Regeneron Q4 2020 Financial Results
[3]: Evaluate Pharma Dupixent Sales Tracker
[4]: Bloomberg Earnings Recap, Feb 2021